A bill for an act concerning private sector employee drug testing. (Formerly HSB 26.) Effective date: 07/01/2025.
Summary
House File 767 amends Iowa’s private-sector drug testing law, Iowa Code section 730.5, to change how employers may notify employees and prospective employees about drug or alcohol test results and related rights. The bill allows employers to offer electronic notification or in-person exchange of written materials instead of requiring certified mail, return receipt requested, for certain notices and employee requests. It also applies this option to notices sent to employees, prospective employees, and parents of minor employees or prospective employees in the testing process.
The bill also revises the definition of “safety-sensitive position” to clarify that it includes jobs designated by the employer where an accident could cause death, serious bodily injury, or significant property or environmental damage, including positions with immediate supervision over such jobs. In addition, it changes the civil remedies section of the law by clarifying that an employer who violates the statute, or aids in a violation, may be liable for equitable relief, attorney fees, and costs, and that the employer bears the burden of proving compliance when a violation is alleged. The bill takes effect July 1, 2025.
Impact
HF 767 updates Iowa Code chapter 730.5, which governs private-sector drug and alcohol testing, by modernizing notice procedures and clarifying enforcement standards. Employers may now use electronic or in-person notice options if offered and chosen, reducing reliance on certified mail, while the bill preserves employee choice and the right to request a second confirmatory test. The measure also strengthens and clarifies civil enforcement by specifying employer liability and burden of proof in actions alleging unlawful testing practices.
Sentiment
The voting history suggests the bill was ultimately enacted despite meaningful opposition. The initial House passage was 60-32, indicating a divided chamber, and an attempt to suspend the rules to consider amendment H-1212 failed 33-59, showing resistance to changing the bill at that stage. The later vote on May 14 passed 31-13, suggesting broader support in the later chamber or final consideration. Overall, the bill appears to have been viewed as a practical update to testing procedures, but not without concern from members who opposed its approach or wanted amendments.
Contention
The main points of contention appear to have been the bill’s changes to notice requirements and enforcement provisions. Opponents likely objected to shifting from certified mail to electronic or in-person notice options, which could affect documentation and procedural protections in drug-testing disputes. The amendment vote indicates there was also disagreement over whether the bill should be modified before passage. Another likely area of debate was the civil remedies section, especially the employer’s burden of proof and potential liability for attorney fees and equitable relief, which may have been seen as either strengthening employee protections or increasing employer exposure.